IMCC Stock Overview
Engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
IM Cannabis Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.61 |
| 52 Week High | CA$8.10 |
| 52 Week Low | CA$1.13 |
| Beta | 1.68 |
| 11 Month Change | 25.41% |
| 3 Month Change | -11.82% |
| 1 Year Change | 9.46% |
| 33 Year Change | -98.93% |
| 5 Year Change | n/a |
| Change since IPO | -97.87% |
Recent News & Updates
Recent updates
IM Cannabis Shareholder Rafael Gabay raises stake
Sep 08IM Cannabis GAAP EPS of -C$0.30, revenue of C$23.8M
Aug 15IM Cannabis receives non-compliance notification from Nasdaq for minimum bid price requirement
Jul 19cbdMD And IM Cannabis Partner To Sell CBD Products In Israeli Markets
Aug 14IM Cannabis proposes public offering of securities
May 05IM Cannabis acquires Israel's largest retail and online pharmacy business from Panaxia
Apr 30Shareholder Returns
| IMCC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -11.5% | 1.6% | 2.2% |
| 1Y | 9.5% | 9.9% | 31.6% |
Return vs Industry: IMCC matched the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: IMCC underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| IMCC volatility | |
|---|---|
| IMCC Average Weekly Movement | 11.0% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: IMCC's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: IMCC's weekly volatility has decreased from 21% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 95 | Oren Shuster | imcannabis.com |
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers medical cannabis dried flowers; and full-spectrum, strain-specific cannabis extracts under the IMC, BLKMT, WAGNERS, and LOT420 brands. The company serves medical patients.
IM Cannabis Corp. Fundamentals Summary
| IMCC fundamental statistics | |
|---|---|
| Market cap | US$7.96m |
| Earnings (TTM) | -US$9.20m |
| Revenue (TTM) | US$36.77m |
0.2x
P/S Ratio-0.9x
P/E RatioIs IMCC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMCC income statement (TTM) | |
|---|---|
| Revenue | CA$51.39m |
| Cost of Revenue | CA$44.78m |
| Gross Profit | CA$6.61m |
| Other Expenses | CA$19.48m |
| Earnings | -CA$12.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.32 |
| Gross Margin | 12.87% |
| Net Profit Margin | -25.03% |
| Debt/Equity Ratio | 360.3% |
How did IMCC perform over the long term?
See historical performance and comparison